Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1844-1855

  Findling, Robert L ^a   Wigal, Sharon B ^b   Bukstein, Oscar G ^c   Boellner, Samuel W ^d   Abikoff, Howard B ^e   Turnbow, John M ^f   Civil, Rich ^g  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Clinical Study Centers LLC   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f Westex Clinical Investigations   (United States)

^g SHIRE   (United States)

Author keywords

attention deficit hyperactivity disorder; children; methylphenidate transdermal system; stimulants

Indexed keywords

CALAMINE; METHYLPHENIDATE;

ADOLESCENT; AGGRESSION; APPLICATION SITE DISCOMFORT; APPLICATION SITE REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CLINICAL TRIAL; CONTACT DERMATITIS; COUGHING; DECREASED APPETITE; DERMATITIS; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ECZEMA; ELECTROCARDIOGRAM; ERYTHEMA; FEMALE; FEVER; HEADACHE; HEART RATE; HUMAN; HYPERPIGMENTATION; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; PARANOID PSYCHOSIS; PATIENT PARTICIPATION; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRURITUS; PSYCHOSIS; QT PROLONGATION; RASH; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SKIN ALLERGY; SORE THROAT; STOMACH PAIN; TACHYCARDIA; TIC; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WEIGHT; WEIGHT REDUCTION;

ADMINISTRATION, CUTANEOUS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 72149089866     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.002     Document Type: Article

References (36)

1. Pelham W.E., Foster E.M., and Robb J.A. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambul Pediatr. 7 Suppl (2007) 121-131
2. Barkley R.A., Fischer M., Edelbrock C., and Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29 (1990) 546-557
3. Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 57 (2005) 1215-1220
4. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 163 (2006) 716-723
5. Wolraich M.L., Wibbelsman C.J., Brown T.E., et al. Attention-deficit/hyperactivity disorder among adolescents: A review of the diagnosis, treatment, and clinical implications. Pediatrics 115 (2005) 1734-1746
6. Minde K., Lewin D., Weiss G., et al. The hyperactive child in elementary school: A 5 year, controlled, followup. Except Child 38 (1971) 215-221
7. Adesman A.R. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry 3 (2001) 66-77
8. Spencer T.J., Biederman J., and Mick E. Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 32 (2007) 631-642
9. Biederman J. Attention-deficit/hyperactivity disorder: A life-span perspective. J Clin Psychiatry 59 Suppl 7 (1998) 4-16
10. Biederman J., Faraone S., Milberger S., et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53 (1996) 437-446
11. Biederman J., Newcorn J., and Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148 (1991) 564-577
12. Johnston C., and Mash E.J. Families of children with attention-deficit/hyperactivity disorder: Review and recommenda tions for future research. Clin Child Fam Psychol Rev 4 (2001) 183-207
13. Swensen A.R., Birnbaum H.G., Secnik K., et al. Attention-deficit/hyperactivity disorder: Increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 42 (2003) 1415-1423
14. Pliszka S., and AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46 (2007) 894-921
15. Pliszka S.R., Crismon M.L., Hughes C.W., et al., Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 642-657
16. American Academy of Pediatrics, and Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108 (2001) 1033-1044
17. Robison L.M., Sclar D.A., Skaer T.L., and Galin R.S. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr (Phila) 38 (1999) 209-217
18. Heal D.J., and Pierce D.M. Methylphenidate and its isomers: Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20 (2006) 713-738
19. Pelham Jr. W.E., Manos M.J., Ezzell C.E., et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 (2005) 522-529
20. Pelham W.E., Burrows-Maclean L., Gnagy E.M., et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 13 (2005) 111-126
21. McGough J.J., Wigal S.B., Abikoff H., et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 9 (2006) 476-485
22. Findling R.L., Bukstein O.G., Melmed R.D., et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder [published correction appears in J Clin Psychiatry. 2008;69:329]. J Clin Psychiatry 69 (2008) 149-159
23. Wilens T.E., Boellner S.W., López F.A., et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47 (2008) 700-708
24. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (2000), American Psychiatric Association, Washington, DC
25. Kaufman J., Birmaher B., Brent D., et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36 (1997) 980-988
26. European Medicines Agency. ICH Topic E 6 (R1). Guideline for Good Clinical Practice. Step 5. Note for Guidance on Good Clinical Practice. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed July 14, 2009
27. Centers for Disease Control and Prevention, and National Center for Health Statistics. National Health and Nutrition Examination Survey. Clinical growth charts. http://www.cdc.gov/nchs/nhanes/growthcharts/clinical_charts.htm Accessed July 16, 2009
28. Owens J.A., Spirito A., and McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep 23 (2000) 1043-1051
29. DuPaul G.J., Power T.J., Anastopoulos A.D., and Reid R. ADHD Rating Scale-IV: Checklists, Norms and Clinical Interpretation (1998), Guilford Press, New York, NY
30. Clinical global impressions. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. DHEW Pub. No. ADM 76-338 (1976), US Dept of Health, Education, and Welfare, Rockville, Md 218-222
31. Wilens T., Pelham W., Stein M., et al. ADHD treatment with once-daily OROS methylphenidate: Interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42 (2003) 424-433
32. McGough J.J., Biederman J., Wigal S.B., et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 (2005) 530-538
33. Kratochvil C.J., Wilens T.E., Greenhill L.L., et al. Effects of long-term atom-oxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 919-927
34. US Food and Drug Administration. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events [press release] (February 21, 2007). http://www.fda.gov/NewsEvents/Newsroom/Press Accessed July 4, 2007
35. Faraone S.V., and Giefer E.E. Long-term effects of methylphenidate trans-dermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 46 (2007) 1138-1147
36. Hoare P., Remschmidt H., Medori R., et al. 12-Month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 14 (2005) 305-309